Momentum Wealth Planning LLC purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) in the first quarter, Holdings Channel reports. The firm purchased 10,819 shares of the company’s stock, valued at approximately $2,645,000. Johnson & Johnson accounts for approximately 2.4% of Momentum Wealth Planning LLC’s holdings, making the stock its 10th largest holding.
Other institutional investors have also recently bought and sold shares of the company. SEB Asset Management AB bought a new position in shares of Johnson & Johnson in the first quarter valued at $314,468,000. Swiss National Bank increased its position in shares of Johnson & Johnson by 7.1% during the first quarter. Swiss National Bank now owns 7,070,707 shares of the company’s stock worth $1,728,364,000 after acquiring an additional 471,100 shares in the last quarter. Precision Wealth Strategies LLC raised its holdings in shares of Johnson & Johnson by 258.7% in the 1st quarter. Precision Wealth Strategies LLC now owns 14,838 shares of the company’s stock worth $3,627,000 after acquiring an additional 10,701 shares during the last quarter. AIA Group Ltd lifted its position in Johnson & Johnson by 11.1% in the 1st quarter. AIA Group Ltd now owns 407,868 shares of the company’s stock valued at $99,699,000 after acquiring an additional 40,831 shares in the last quarter. Finally, Mediolanum International Funds Ltd lifted its position in Johnson & Johnson by 4.7% in the 1st quarter. Mediolanum International Funds Ltd now owns 410,637 shares of the company’s stock valued at $99,575,000 after acquiring an additional 18,460 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.
Insiders Place Their Bets
In related news, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the sale, the executive vice president owned 114,288 shares in the company, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.16% of the company’s stock.
Key Stories Impacting Johnson & Johnson
- Positive Sentiment: J&J’s robust Q2 performance beat estimates for both earnings and revenue, prompting the company to raise its 2026 outlook and reinforcing confidence in its core pharmaceuticals and MedTech businesses. Article: Should You Buy, Sell or Hold J&J’s Stock Post a Robust Q2 Performance?
- Positive Sentiment: New MedTech developments, including an acquisition in spine technologies and FDA approval for a heart-device platform, add to J&J’s growth story and expand its medical device portfolio. Article: Johnson & Johnson (JNJ) Buys Spine Tech And Wins FDA Nod For Heart Device
- Positive Sentiment: Several articles framed J&J as a long-term defensive holding, citing its diversified healthcare footprint, AAA-like balance sheet strength, and 64-year dividend growth streak, which can support investor demand during market volatility. Article: Why Johnson & Johnson Is a Stock You Can Own Forever
Analysts Set New Price Targets
JNJ has been the subject of a number of recent research reports. Sanford C. Bernstein boosted their price objective on Johnson & Johnson from $225.00 to $251.00 and gave the stock a “market perform” rating in a report on Wednesday, April 15th. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday. Freedom Capital upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 16th. Morgan Stanley raised their price objective on Johnson & Johnson from $284.00 to $294.00 and gave the company an “overweight” rating in a research note on Thursday. Finally, Wells Fargo & Company lifted their price objective on shares of Johnson & Johnson from $263.00 to $272.00 and gave the stock an “overweight” rating in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $265.30.
Johnson & Johnson Stock Performance
Shares of JNJ opened at $248.83 on Tuesday. The stock has a 50 day moving average of $240.37 and a 200 day moving average of $235.11. The company has a market capitalization of $598.99 billion, a price-to-earnings ratio of 28.83, a PEG ratio of 2.39 and a beta of 0.24. Johnson & Johnson has a 12 month low of $162.78 and a 12 month high of $269.43. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.84 by $0.06. The business had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a return on equity of 32.86% and a net margin of 21.48%.The business’s revenue was up 6.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 11.68 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson’s payout ratio is 62.11%.
Johnson & Johnson Company Profile
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
- Is Domino’s Stock Serving Up a Buying Opportunity?
- A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free
- Why Gold Miners Could Be the Market’s Biggest Comeback Story
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
